阿托伐他汀对急性冠脉综合征患者血清基质金属蛋白酶-9的影响

The Atorvastatin Affect Serum Matrix Metalloproteinase-9 Level in Acute Coronary Syndrome Patients

目的:观察急性冠脉综合征(ACS)患者经过阿托伐他汀治疗后其血清基质金属蛋白酶-9(MMP-9)的变化情况。方法:确诊为ACS患者90例为研究组,其中不稳定型心绞痛(UAP组)患者45例、急性心肌梗死(AMI组)患者45例入院后均在基础治疗的同时给予阿托伐他汀20 mg,每晚口服1次治疗,测定其治疗前后血清MMP-9水平。同时选取30例健康人为对照组,同样测定血清MMP-9水平。结果:研究组血清MMP-9水平明显高于对照组(P<0.01);治疗后,UAP组和AMI组血清MMP-9水平均比治疗前明显降低(P<0.01)。结论:阿托伐他汀能够明显降低ACS患者的血清MMP-9水平,在动脉粥样硬化斑块的稳定性方面可能发挥一定的作用。

Objective： To observe serum matrix metalloproteinase -9 （ MMP-9 ） level in the acute coronary syndrome （ ACS ） patients after atorvastatin therapy. Method： 90 ACS patients for the study group, unstable angina pectoris 45 cases （ UAP group ） and acute myocardial infarction 45 cases （ AMI group ）, were admitted to hospital .except for the basic treatment, each patient was taken 20mg atorvastatin one day, and was measured the serum MMP-9 level before and after treatment. 30 patients healthy control group was measured serum MMP-9 level. Result： Study group serum MMP-9 levels was significantly higher than that in the control group （ P〈0.01 ） ; Both of the UAP group and AMI group serum level of MMP-9 was significantly lower than pretreatment （ P〈0.01 ） .Conclusion： Atorvastatin significantly reduces serum MMP-9 level in patients with ACS, and plays a role in atherosclerotic plaque stability.